Brean Capital analyst Difei Yang weighed in today with her thoughts on Conatus Pharmaceuticals Inc (NASDAQ:CNAT), after the company announces the appointment of Dr. Jean Chan to …
Conatus Pharmaceuticals Inc (NASDAQ:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced the appointment of …
Conatus Pharmaceuticals Inc (NASDAQ:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results …
Conatus Pharmaceuticals Inc (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced the completion of its …
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced that three posters addressing clinical results with emricasan, the company’s first-in-class, orally active pan-caspase protease inhibitor, have been …
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) announced today its scheduled presentation of the company's programs and outlook at the 14th Annual Needham Healthcare Conference on Wednesday, April …
Conatus Pharmaceuticals Inc. (NADAQ:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced today that …
Conatus Pharmaceuticals Inc (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced that it …
MLV’s healthcare analyst Vernon Bernardino weighed in with an optimistic view on Conatus Pharmaceuticals Inc (NASDAQ:CNAT), after the company announced positive top-line results from its double-blind, placebo-controlled …
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) today announced top-line results from the company's Phase 2 double-blind, placebo-controlled clinical trial of emricasan, a first-in-class, orally active …
